Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
Authors
Keywords
HIV-1, Antiretrovirals, Antimicrobial resistance, Drug therapy, Mutation, Antiretroviral therapy, Sequence analysis, Sequence databases
Journal
PLoS One
Volume 12, Issue 2, Pages e0172206
Publisher
Public Library of Science (PLoS)
Online
2017-02-18
DOI
10.1371/journal.pone.0172206
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
- (2016) Nicolas A. Margot et al. HIV CLINICAL TRIALS
- Differences among HIV-1 subtypes in drug resistance against integrase inhibitors
- (2016) Ying-Shan Han et al. INFECTION GENETICS AND EVOLUTION
- Brief Report
- (2016) David Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2016) Huldrych F. Günthard et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
- (2016) Soo-Yon Rhee et al. JOURNAL OF VIROLOGY
- Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir ResistanceIn Vitro
- (2015) Takahiro Seki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance
- (2015) Atsuko Hachiya et al. ANTIVIRAL RESEARCH
- Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection
- (2015) Tae Eun Park et al. Expert Review of Anti-Infective Therapy
- Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment
- (2015) Frank A. Post et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Brief Report
- (2015) Sharon Walmsley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals
- (2015) Teresa Llácer Delicado et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients
- (2015) Rima Kulkarni et al. HIV CLINICAL TRIALS
- Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007–2013
- (2014) Joanne D Stekler et al. ANTIVIRAL THERAPY
- Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
- (2014) Kirsten L White et al. ANTIVIRAL THERAPY
- Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy
- (2014) Paul E. Sax et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance
- (2014) I. Hardy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Prevalent Polymorphisms in Wild-Type HIV-1 Integrase Are Unlikely To Engender Drug Resistance to Dolutegravir (S/GSK1349572)
- (2013) Cindy Vavro et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to Elvitegravir
- (2013) Wei Huang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
- (2013) Michael E. Abram et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009–2012
- (2013) Christopher B. Hurt et al. CLINICAL INFECTIOUS DISEASES
- HIV-1 drug resistance: where do polymorphisms fit in?
- (2013) Kristof Theys et al. Future Microbiology
- Prevalence of Primary Resistance Mutations to Integrase Inhibitors in Treatment-Naïve and -Experienced Patients Infected With B and Non-B HIV-1 Variants
- (2013) Carolina Gutiérrez et al. HIV CLINICAL TRIALS
- A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
- (2013) Anne-Geneviève Marcelin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) David A. Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Nathan Clumeck et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen
- (2012) Jaqueline Souza Cavalcanti et al. ANTIVIRAL RESEARCH
- The HIVdb System for HIV-1 Genotypic Resistance Interpretation
- (2012) Michele W. Tang et al. INTERVIROLOGY
- HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes
- (2012) S. Reigadas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing
- (2012) Daniele Armenia et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In Vivo
- (2012) S. Fransen et al. JOURNAL OF VIROLOGY
- Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
- (2012) Mark A. Winters et al. PLoS One
- The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance
- (2012) Matthias Götte Current Opinion in Virology
- Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies
- (2011) Jürgen K. Rockstroh et al. AIDS
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- (2011) Calvin Cohen et al. AIDS
- Single Mutations in HIV Integrase Confer High-Level Resistance to Raltegravir in Primary Human Macrophages
- (2011) Matthew D. Marsden et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structure-Analysis of the HIV-1 Integrase Y143C/R Raltegravir Resistance Mutation in Association with the Secondary Mutation T97A
- (2011) S. Reigadas et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience
- (2011) Carolina Garrido et al. ANTIVIRAL RESEARCH
- Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy
- (2011) Benjamin Young et al. ANTIVIRAL THERAPY
- Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule
- (2011) Christopher B Hurt ANTIVIRAL THERAPY
- Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient
- (2011) Sarita D Boyd et al. ANTIVIRAL THERAPY
- Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir
- (2011) Srinivasan Ramanathan et al. CLINICAL PHARMACOKINETICS
- Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients
- (2011) I. Malet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evolutionary pathways of transmitted drug-resistant HIV-1
- (2011) M. Pingen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
- (2011) Jose-Luis Blanco et al. JOURNAL OF INFECTIOUS DISEASES
- Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors
- (2011) Bluma G. Brenner et al. JOURNAL OF MEDICAL VIROLOGY
- Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
- (2011) Linda Wittkop et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
- (2011) Jean-Michel Molina et al. LANCET INFECTIOUS DISEASES
- Development of Antiretroviral Drug Resistance
- (2011) Mark A. Wainberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
- (2011) Antonio Piralla et al. Virology Journal
- HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
- (2010) Tamara Bar-Magen et al. AIDS
- HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients and in Triple-Class Experienced Patients Subsequently Treated with Raltegravir
- (2010) Vici Varghese et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors
- (2010) F. Ceccherini-Silberstein et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment
- (2010) Jia Liu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure
- (2010) Francisco M. Codoñer et al. ANTIVIRAL RESEARCH
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption
- (2010) F. Canducci et al. CLINICAL MICROBIOLOGY AND INFECTION
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution
- (2010) J. A. Johnson et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
- (2010) Francesca Ceccherini-Silberstein et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir
- (2010) Filippo Canducci et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
- (2010) Andrew R. Zolopa et al. JOURNAL OF INFECTIOUS DISEASES
- The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions
- (2010) Sandrine Reigadas et al. PLoS One
- Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies
- (2009) Filippo Canducci et al. AIDS
- Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors
- (2009) A. Low et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients
- (2009) Jose R Arribas et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time
- (2009) Viviane D Lima et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
- (2009) I. Malet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evolution of raltegravir resistance during therapy
- (2009) N. Sichtig et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection
- (2009) C. Garrido et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment–Naive Patients Significantly Impact Treatment Outcomes
- (2009) Birgitte B. Simen et al. JOURNAL OF INFECTIOUS DISEASES
- Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways
- (2009) S. Fransen et al. JOURNAL OF VIROLOGY
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
- (2009) O. Delelis et al. NUCLEIC ACIDS RESEARCH
- HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins
- (2009) Zabrina L. Brumme et al. PLoS One
- HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure
- (2009) Sebastiaan J van Hal et al. Retrovirology
- Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility
- (2008) Kurt Van Baelen et al. AIDS
- Emerging Pharmacology: Inhibitors of Human Immunodeficiency Virus Integration
- (2008) Daria Hazuda et al. Annual Review of Pharmacology and Toxicology
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro
- (2008) I. Malet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics
- (2008) Koichiro Nakahara et al. ANTIVIRAL RESEARCH
- Minority Quasispecies of Drug‐Resistant HIV‐1 That Lead to Early Therapy Failure in Treatment‐Naive and ‐Adherent Patients
- (2008) Karin J. Metzner et al. CLINICAL INFECTIOUS DISEASES
- Preexisting Resistance to Nonnucleoside Reverse‐Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz‐Based Regimen in Treatment‐Naive HIV‐1–Infected Subjects
- (2008) Daniel R. Kuritzkes et al. JOURNAL OF INFECTIOUS DISEASES
- Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 Integrase
- (2008) R. E. Myers et al. JOURNAL OF VIROLOGY
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy
- (2008) Jeffrey A Johnson et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search